GLP-1 Drug Exenatide Reduced Lipedema Symptoms and Fat Thickness in Italian Case Series
Exenatide reduced lipedema symptoms, pain, and subcutaneous fat thickness in five women with insulin resistance, even in some cases without weight loss.
Quick Facts
What This Study Found
Exenatide reduced lipedema symptoms, evoked pain, and ultrasound-measured subcutaneous fat thickness in legs, abdomen, and arms, including in patients without weight loss.
Key Numbers
5 women with lipedema and insulin resistance. Exenatide once weekly for 3-6 months. Reduced symptoms, pinch-test pain, and ultrasound-measured fat thickness at lower limbs, abdomen, and upper limbs. 4/5 had weight reduction.
How They Did This
Case series of 5 women with lipedema and insulin resistance treated with once-weekly exenatide for 3-6 months, with assessment of anthropometric parameters, symptoms, clinical findings, and ultrasound-measured adipose tissue thickness.
Why This Research Matters
Lipedema has no approved pharmacological treatment. This case series suggests GLP-1 drugs may address the disease directly — not just through weight loss — by targeting the metabolic dysfunction underlying abnormal fat accumulation.
The Bigger Picture
If confirmed in larger studies, GLP-1 receptor agonists could become the first pharmacological treatment for lipedema, a condition that currently relies on compression garments, manual therapy, and liposuction.
What This Study Doesn't Tell Us
Very small case series (n=5) without a control group. Cannot distinguish between drug effects and lifestyle changes. Improvements may not be generalizable to all lipedema patients.
Questions This Raises
- ?Would semaglutide or tirzepatide be even more effective for lipedema given their stronger weight loss effects?
- ?What mechanism explains fat reduction in lipedema patients who did not lose overall weight?
Trust & Context
- Key Stat:
- Improvements without weight loss Some patients showed reduced lipedema symptoms and fat thickness even without losing body weight, suggesting direct effects on abnormal fat tissue
- Evidence Grade:
- Case series of 5 patients — low-level evidence. Results are hypothesis-generating and need confirmation in larger controlled studies.
- Study Age:
- Published in 2025, representing early clinical exploration of GLP-1 drugs for lipedema.
- Original Title:
- A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.
- Published In:
- Clinics and practice, 15(7) (2025)
- Authors:
- Patton, Laura, Reverdito, Valeria, Bellucci, Alessandra, Bortolon, Micaela, Macrelli, Annalisa, Ricolfi, Lorenzo
- Database ID:
- RPEP-12988
Evidence Hierarchy
Frequently Asked Questions
What is lipedema and why is it hard to treat?
Lipedema is a chronic condition causing painful, disproportionate fat accumulation, mainly in the legs and arms, that does not respond to diet and exercise. It predominantly affects women and has no approved drug treatment — current options are limited to compression, manual therapy, and liposuction.
Could GLP-1 drugs become a treatment for lipedema?
This small case series suggests they might. Exenatide reduced symptoms and fat thickness in all five patients, even without weight loss in some cases. Larger clinical trials are needed to confirm these promising early findings.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12988APA
Patton, Laura; Reverdito, Valeria; Bellucci, Alessandra; Bortolon, Micaela; Macrelli, Annalisa; Ricolfi, Lorenzo. (2025). A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.. Clinics and practice, 15(7). https://doi.org/10.3390/clinpract15070128
MLA
Patton, Laura, et al. "A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.." Clinics and practice, 2025. https://doi.org/10.3390/clinpract15070128
RethinkPeptides
RethinkPeptides Research Database. "A Case Series on the Efficacy of the Pharmacological Treatme..." RPEP-12988. Retrieved from https://rethinkpeptides.com/research/patton-2025-a-case-series-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.